Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion

Journal of Physiology and Biochemistry

Volumn 70, Issue 3, 2014, Pages 667-674

  Quintero, Pablo ^a   Pizarro, Margarita ^a   Solís, Nancy ^a   Arab, Juan Pablo ^a   Padilla, Oslando ^a   Riquelme, Arnoldo ^a   Arrese, Marco ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Bile; Incretins; Insulin resistance; Steatosis

Indexed keywords

ABC TRANSPORTER; ABCB11 PROTEIN, RAT; BILE ACID; CELL RECEPTOR; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLIC ACID; COTRANSPORTER; CYP7A1 PROTEIN, RAT; GLUCAGON LIKE PEPTIDE 1; INCRETIN; NUCLEAR RECEPTOR SUBFAMILY 0, GROUP B, MEMBER 2; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

ANIMAL; BLOOD; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GLUCOSE TOLERANCE TEST; LIVER; MALE; METABOLISM; MOUSE; MOUSE MUTANT; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE ACIDS AND SALTS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CHOLIC ACID; GENE EXPRESSION; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; INCRETINS; LIVER; MALE; MICE; MICE, OBESE; NON-ALCOHOLIC FATTY LIVER DISEASE; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SYMPORTERS; TRIGLYCERIDES; URSODEOXYCHOLIC ACID;

EID: 84933037432     PISSN: 11387548     EISSN: 18778755     Source Type: Journal    
DOI: 10.1007/s13105-014-0336-1     Document Type: Article

References (43)

1. Adorini L, Pruzanski M, Shapiro D (2012) Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 17–18:988–97
2. Allain CC, Poon LS, Chan CS, Richmond W et al (1974) Enzymatic determination of total serum cholesterol. Clin Chem 4:470–5
3. Anderson ME (1985) Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 548–55
4. Anstee QM, Targher G, Day CP (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol
5. Arrese M (2010) Nonalcoholic fatty liver disease: liver disease: an overlooked complication of diabetes mellitus. Nat Rev Endocrinol 12:660–1
6. Baginski ES, Foa PP, Zak B (1967) Microdetermination of inorganic phosphate, phospholipids, and total phosphate in biologic materials. Clin Chem 4:326–32
7. Bernsmeier C, Meyer-Gerspach AC, Blaser LS, Jeker L et al (2014) Glucose-induced glucagon-like peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS ONE 1:e87488
8. Carr TP, Andresen CJ, Rudel LL (1993) Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem 1:39–42
9. Cipriani S, Mencarelli A, Palladino G, Fiorucci S (2010) FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 4:771–84
10. Chalasani N, Younossi Z, Lavine JE, Diehl AM et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 7:1592–609
11. DeLeve LD, Kaplowitz N (1991) Glutathione metabolism and its role in hepatotoxicity. Pharmacol Ther 3:287–305
12. Diehl AM (2004) Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 3:619–38
13. Furukawa S, Fujita T, Shimabukuro M, Iwaki M et al (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 12:1752–61
14. Goodwin B, Jones SA, Price RR, Watson MA et al (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 3:517–26
15. Gupta NA, Mells J, Dunham RM, Grakoui A et al (2010) Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 5:1584–92
16. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 4:1409–39
17. Ibanez P, Solis N, Pizarro M, Aguayo G et al (2007) Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 6:846–51
18. Ikemoto S, Takahashi M, Tsunoda N, Maruyama K et al (1997) Cholate inhibits high-fat diet-induced hyperglycemia and obesity with acyl-CoA synthetase mRNA decrease. Am J Physiol 1(Pt 1):E37–45
19. Ishizaki K, Iwaki T, Kinoshita S, Koyama M et al (2008) Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production. Eur J Pharmacol 1:57–64
20. Kars M, Yang L, Gregor MF, Mohammed BS et al (2010) Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes 8:1899–905
21. Lefebvre P, Cariou B, Lien F, Kuipers F et al (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 1:147–91
22. Liechti F, Dufour JF (2012) Treatment of NASH with ursodeoxycholic acid: cons. Clin Res Hepatol Gastroenterol S46-52
23. Matsubara T, Li F, Gonzalez FJ (2013) FXR signaling in the enterohepatic system. Mol Cell Endocrinol 1–2:17–29
24. McConnachie LA, Mohar I, Hudson FN, Ware CB et al (2007) Glutamate cysteine ligase modifier subunit deficiency and gender as determinants of acetaminophen-induced hepatotoxicity in mice. Toxicol Sci 2:628–36
25. Nie B, Park HM, Kazantzis M, Lin M et al (2012) Specific bile acids inhibit hepatic fatty acid uptake in mice. Hepatology 4:1300–10
26. Olaywi M, Bhatia T, Anand S, Singhal S (2013) Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. Hepatobiliary Pancreat Dis Int 6:584–8
27. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M et al (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 5790:1137–40
28. Pols TW, Noriega LG, Nomura M, Auwerx J et al (2011) The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol 6:1263–72
29. Pols TW, Noriega LG, Nomura M, Auwerx J et al (2011) The bile acid membrane receptor TGR5: a valuable metabolic target. Dig Dis 1:37–44
30. Rafferty EP, Wylie AR, Hand KH, Elliott CE et al (2011) Investigating the effects of physiological bile acids on GLP-1 secretion and glucose tolerance in normal and GLP-1R(−/−) mice. Biol Chem 6:539–46
31. Ratziu V (2012) Treatment of NASH with ursodeoxycholic acid: pro. Clin Res Hepatol Gastroenterol S41-5
32. Stepanova M, Rafiq N, Makhlouf H, Agrawal R et al (2013) Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 10:3017–23
33. Talalay P (1960) Enzymic analysis of steroid hormones. Methods Biochem Anal 119–43
34. Thomas C, Pellicciari R, Pruzanski M, Auwerx J et al (2008) Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 8:678–93
35. Trauner M, Arrese M, Wagner M (2010) Fatty liver and lipotoxicity. Biochim Biophys Acta 3:299–310
36. Trauner M, Claudel T, Fickert P, Moustafa T et al (2010) Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 1:220–4
37. Tsuchida T, Shiraishi M, Ohta T, Sakai K et al (2012) Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. Metab Clin Exp 7:944–53
38. Turley SD, Dietschy JM (1978) Re-evaluation of the 3 alpha-hydroxysteroid dehydrogenase assay for total bile acids in bile. J Lipid Res 7:924–8
39. Watanabe M, Houten SM, Wang L, Moschetta A et al (2004) Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 10:1408–18
40. Xiang Z, Chen YP, Ma KF, Ye YF, et al. (2013) The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol 140
41. Yang JS, Kim JT, Jeon J, Park HS et al (2010) Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice. PLoS ONE 11:e13858
42. Zhang Y, Klaassen CD (2010) Effects of feeding bile acids and a bile acid sequestrant on hepatic bile acid composition in mice. J Lipid Res 11:3230–42
43. Zollner G, Wagner M, Moustafa T, Fickert P et al (2006) Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol 5:G923–32